Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines
–Through a partnership with antisense pioneer Agrawal’s Arnay Sciences, Alloy strengthens its mission to democratize enabling drug discovery technology for the global scientific community– BOSTON, MA; June 09, 2022–Alloy Therapeutics, a biotechnology ecosystem company, announced a collaboration and licensing agreement with Sudhir Agrawal’s Arnay Sciences to advance new RNA-based drug discovery platforms and novel chemistries spanning […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Biotech ecosystem company Alloy Therapeutics leads the round, joined by Uncommon Denominator and Mytide founders BOSTON, March 8th, 2021–Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics
BOSTON, MA & OKLAHOMA CITY, OK, July 21st, 2021 – Alloy Therapeutics and Echo Investment Capital today announced the formation of Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact. Wheeler’s comprehensive discovery-to-IND programs are designed to provide emerging biopharma companies a faster and more predictable path […]
Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing
Seed Financing Will Scale Company’s Technology and Business Operations to Serve Clients of All Stages BURLINGTON, VT, July 12th, 2021 – Vernal Biosciences, Inc., a manufacturer of high purity mRNA for research and clinical use, today announced the closing of a seed round of financing. Alloy Therapeutics led the round and was joined by the […]
Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and Pyxis Oncology (“Pyxis”) today announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases. Voxall Therapeutics will advance programs directed to immune-modulating targets identified by Pyxis. Alloy Discovery Services will generate […]
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
Funds to be used to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.
Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases
Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases.
